Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4528287 in Healthy Participants
NCT06681181Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK4528287 in ulcerative colitis (UC) and Crohn's disease (7 arms), sponsored by GSK. Primary endpoints: Adverse Events, Serious Adverse Events and 4 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
GSK4528287
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT06681181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681181.